Pfizer Inc
NYSE : PFE$29.58−0.04%Oct 16 close
Financials
Consolidated Balance Sheets
USD · reported units. Click a value to inspect its source.
| Reported line item | Dec 31, 2023 (current) | Dec 31, 2022 |
|---|---|---|
| Cash and cash equivalents | ||
| Short-term investments | ||
| Trade accounts receivable, less allowance for doubtful accounts: 2023$470; 2022$449 | ||
| Inventories | ||
| Current tax assets | ||
| Other current assets | ||
| Total current assets | ||
| Equity-method investments | ||
| Long-term investments | ||
| Property, plant and equipment | ||
| Identifiable intangible assets | ||
| Goodwill | ||
| Noncurrent deferred tax assets and other noncurrent tax assets | ||
| Other noncurrent assets | ||
| Total assets | ||
| Short-term borrowings, including current portion of long-term debt: 2023$2,254; 2022$2,560 | ||
| Trade accounts payable | ||
| Dividends payable | ||
| Income taxes payable | ||
| Accrued compensation and related items | ||
| Deferred revenues | ||
| Other current liabilities | ||
| Total current liabilities | ||
| Long-term debt | ||
| Pension and postretirement benefit obligations | ||
| Noncurrent deferred tax liabilities | ||
| Other taxes payable | ||
| Other noncurrent liabilities | ||
| Total liabilities | ||
| Commitments and Contingencies | — | — |
| Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022 | ||
| Common stock, $0.05 par value; 12,000 shares authorized; issued: 20239,562; 20229,519 | ||
| Additional paid-in capital | ||
| Treasury stock, shares at cost: 20233,916; 20223,903 | ||
| Retained earnings | ||
| Accumulated other comprehensive loss | ||
| Total Pfizer Inc. shareholders equity | ||
| Equity attributable to noncontrolling interests | ||
| Total equity | ||
| Total liabilities and equity |
40 line items · 2 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.
Arithmetic validation is incomplete for this statement. Source values remain individually inspectable.